Orient EuroPharma Co., Ltd.

President & CEO: Peter Tsai
Founded in: 16 June, 1982
Tel: 886-2-2755-4881 
Fax: 886-2-2702-4324
Address: 7F., No. 368, Sec. 1 Fu Hsing S. Rd.,Taipei 106, Taiwan, R.O.C.
Website: http://www.oep.com.tw/


About OEP:

Founded in 1982, Orient EuroPharma Co., Ltd (OEP) was officially listed in the Gre-Tai Securities market in 2003, and consolidated net sales exceeded $4.6 billion in the 2013 financial year. OEP’s products include pharmaceuticals, cancer drugs, cosmeceutical, infant & adult nutrition and healthcare products. Currently, OEP has more than 760 staffs worldwide, in which over 40% are overseas employees. OEP named as one of the top three benchmark biotechnology by the Institute for Biotechnology and Medicine Industry in 2013 and ranked the top one thousand large enterprises named by the CommonWealth Magazine from 2012 to 2014.

The subsidiary company OrientPHARMA Co., Ltd (OP) was founded in 2008 for developing and manufacturing new drugs. In 2012, OEP expanded its R&D capabilities in the cancer drug area, and signed an agreement with Japan NanoCarrier Co., Ltd. to jointly develop new cancer drugs. In 2013, OPNano Co., Ltd (ON) established, and the new injection plant began construction in 2014. 

The OP plant is allocated in Huwei Park in Yunlin and has got the certifications of Taiwan PIC/S GMP, the “Accreditation Certification of Foreign Drug Manufacturer” from US FDA international standards. The OP focus on development of new drugs which fulfill the standards set by US FDA, including anti-psychotics, drugs for treating Alzheimer’s disease, psychostimulants, and drugs for treating Parkinson’s disease. 2014, muscle relaxant drug Carisoprodol tablets get the license form US FDA. 

With the globalizing and growing market, OEP started to establish overseas subsidiaries in Singapore, Malaysia, Hong Kong and the Philippines since 1993. In 2006, OEP established the subsidiaries in Shanghai and Guangdong. In 2011, OEP expanded its market to Vietnam and planned to expand to Sri Lanka, Cambodia, Myanmar and India, strengthening OEP’s marketing and sales capability in the Asian Pacific region.

R&D Pipeline in OEP

Clinical Trial No.





Head-Neck Cancer

The study will be the first clinical trial to enhance patient's immunity and weaken the tumor activity before the standard of treatment (surgery plus radiotherapy or concurrent chemoradiotherapy).

Phase III


Pancreatic Cancer

NC-6004-005 is a new platinum-based micelle chemotherapeutic drug.

Phase III



ASC-J9 is a small molecular new chemical entity drug with new mechanism.

Phase II


Intradialysis Hypotension

NOX-100-ORIENT201 is a small molecular new chemical entity drug with new mechanism.

Phase II